Quince Therapeutics’ (QNCX) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report sent to investors on Tuesday, Marketbeat.com reports. Cantor Fitzgerald currently has a $70.00 price target on the stock.

Other equities research analysts also recently issued reports about the stock. Zacks Research raised shares of Quince Therapeutics to a “hold” rating in a research note on Wednesday, June 24th. Lifesci Capital raised shares of Quince Therapeutics to a “strong-buy” rating in a research report on Monday, June 29th. Wall Street Zen upgraded shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Leerink Partners assumed coverage on Quince Therapeutics in a research report on Wednesday, June 24th. They set an “outperform” rating and a $80.00 price objective on the stock. Finally, Weiss Ratings upgraded Quince Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $260.00.

Quince Therapeutics Price Performance

Shares of NASDAQ:QNCX opened at $32.11 on Tuesday. The firm has a market capitalization of $32.75 million, a PE ratio of -0.20 and a beta of 1.36. The firm’s 50-day moving average is $22.15 and its two-hundred day moving average is $24.93. Quince Therapeutics has a 1 year low of $15.10 and a 1 year high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Friday, August 14th. The company reported ($12.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($28.02) by $15.71.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC grew its holdings in Quince Therapeutics by 21.6% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,073,729 shares of the company’s stock worth $5,010,000 after acquiring an additional 545,427 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Quince Therapeutics in the 4th quarter valued at approximately $7,538,000. Vanguard Group Inc. raised its holdings in shares of Quince Therapeutics by 21.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock valued at $2,874,000 after purchasing an additional 309,349 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Quince Therapeutics by 1,152.9% in the 3rd quarter. Millennium Management LLC now owns 1,386,776 shares of the company’s stock valued at $2,260,000 after purchasing an additional 1,276,094 shares in the last quarter. Finally, Almitas Capital LLC lifted its position in shares of Quince Therapeutics by 88.0% during the 4th quarter. Almitas Capital LLC now owns 930,134 shares of the company’s stock worth $3,116,000 after purchasing an additional 435,356 shares during the last quarter. Hedge funds and other institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.